Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

2023; Frontiers Media; Volume: 14; Linguagem: Inglês

10.3389/fimmu.2023.1125030

1664-3224

Alessandro Busca, Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, Güldane Cengiz Seval, Jaap A. van Doesum, Nick de Jonge, Nathan C. Bahr, Johan Maertens, Joseph Meletiadis, Nicola Fracchiolla, Barbora Weinbergerová, Luisa Verga, Zdeněk Ráčil, Moraima Jiménez, Andreas Glenthøj, Ola Blennow, Alina Tănase, Martin Schönlein, Lucia Prezioso, Nina Khanna, Rafael F. Duarte, Павел Зак, Márcio Nucci, Marina Machado, Austin Kulasekararaj, Ildefonso Espigado, Elizabeth de Kort, José-María Ribera-Santa Susana, Monia Marchetti, Gabriele Magliano, Iker Falces‐Romero, Osman İlhan, Emanuele Ammatuna, Sofia Zompi, Panagiotis Tsirigotis, Anastasia Antoniadou, Giovanni Paolo Maria Zambrotta, Anna Nordlander, Linda Karlsson, Michaela Hanáková, Giulia Dragonetti, Alba Cabirta, Caroline Berg Venemyr, Stefanie K. Gräfe, Jens Van Praet, Athanasios Tragiannidis, Verena Petzer, Alberto López‐García, Federico Itri, Ana Groh, Eleni Gavriilaki, Michelina Dargenio, Laman Rahimli, Oliver A. Cornely, Livio Pagano,

Neutropenia and Cancer Infections

The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT.This multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022.The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53).Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.